

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

APC/Fire(TM) 810 anti-human CD27 Recombinant

RRID:AB_2860961

Type: Antibody

Proper Citation

BioLegend Cat# 393213, RRID:AB_2860961

Antibody Information

URL: http://antibodyregistry.org/AB_2860961

Proper Citation: BioLegend Cat# 393213, RRID:AB_2860961

Target Antigen: CD27

Host Organism: mouse

Clonality: recombinant monoclonal

Comments: Applications: FC

Antibody Name: APC/Fire(TM) 810 anti-human CD27 Recombinant

Description: This recombinant monoclonal targets CD27

Target Organism: human

Clone ID: Clone QA17A18

Antibody ID: AB_2860961

Vendor: BioLegend

Catalog Number: 393213

Alternative Catalog Numbers: 393214

Record Creation Time: 20231110T032034+0000

Record Last Update: 20260901T033511+0000

Ratings and Alerts

No rating or validation information has been found for APC/Fire(TM) 810 anti-human CD27 Recombinant.

No alerts have been found for APC/Fire(TM) 810 anti-human CD27 Recombinant.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Freeburg NF, et al. (2026) The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM. Cell.

Ngiow SF, et al. (2024) LAG-3 sustains TOX expression and regulates the CD94/NKG2-Qa-1b axis to govern exhausted CD8 T cell NK receptor expression and cytotoxicity. Cell, 187(16), 4336.

Wang K, et al. (2024) Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells. Cancer cell, 42(9), 1582.